SynthesisFrontiers in medicine2025
Prognostic biomarkers for predicting decompensation in alcoholic and non-alcoholic patients with compensated cirrhosis: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Biomarkers for Predicting Decompensation in Alcoholic and Nonalcoholic Patients With Compensated Cirrhosis: An Umbrella Review.Biochemistry research international · 2026Review
- Oxidative Stress in Liver Metabolic Dysfunction and Diseases, with a Focus on Hepatogenic Diabetes: Effect of Alcohol Consumption.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic decompensation is a critical turning point in the progression of compensated cirrhosis, with distinct pathophysiological trajectories in alcoholic and non-alcoholic etiologies. This systematic review and meta-analysis evaluates prognostic biomarkers for predicting decompensation in patients with compensated cirrhosis, emphasizing differences between alcoholic and non-alcoholic liver disease. Methods: Following PRISMA 2020 guidelines, we systematically searched PubMed, Scopus, and Web of Science for peer-reviewed studies (up to April 2025) reporting hazard ratios (HRs) and 95% confidence intervals for biomarkers predicting decompensation in adults with compensated cirrhosis. Eligible studies included observational cohorts and control arms of RCTs, stratified by etiology (alcoholic vs. non-alcoholic). Data were pooled using random-effects models, with heterogeneity assessed via Results: From 691 records, 66 studies (Among these, 955 patients (2.6%) were alcoholic and 36,108 (97.4%) non-alcoholic, totaling 37,063 participants) were included. In non-alcoholic cirrhosis, structural biomarkers like portal vein diameter (HR = 7.39 [4.90, 11.15]) and spleen size (HR = 5.79 [2.00, 16.80]) were strong predictors, alongside functional markers such as bilirubin (HR = 4.27 [2.93, 6.22]) and MELD score (HR = 1.13 [1.07, 1.20]). In alcoholic cirrhosis, inflammatory biomarkers, particularly extracellular vesicles (HR = 5.09 [2.01, 12.86]) and keratin-18 (HR = 1.77 [1.14, 2.75]), showed superior predictive value. Interleukin-6 was predictive across both etiologies (HR = 1.31 [1.00, 1.71]). Heterogeneity was substantial ( Conclusion: Etiology-specific biomarkers enhance prognostic accuracy in compensated cirrhosis. Structural and functional markers dominate in non-alcoholic cirrhosis, while inflammatory biomarkers are more predictive in alcoholic cirrhosis. Integrating these into personalized risk models could improve clinical management, though prospective validation is needed. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251076849.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.